Acknowledgments
This study is conducted with the free supply of the research drug (Firazyl® subcutaneous injection 30 mg syringe) from Takeda Pharmaceuticals International AG, a subsidiary of Takeda Pharmaceutical Company Limited. It is supported by Clinical Research Center in Hiroshima. We offer a special thank you also to all the staff involved in this study.